Physician profile
Robert G Thomas
NPI 1720284508
$1,579.83
in general payments reported to CMS, 2019-2025
18 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312 · Education: $59.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.87 |
| Education | $59.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $182.25 | 2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $174.65 | 2025 | Neffy |
| Neurent Medical Limited | $168.45 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Astrazeneca Pharmaceuticals LP | $163.81 | 2025 | Airsupra |
| Ethicon US, LLC | $152.81 | 2025 | Linx Reflux Management System |
| Genzyme Corporation | $149.53 | 2025 | |
| Aerin Medical INC. | $132.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.81 | 2025 | Dupixent |
| Acclarent, INC | $84.75 | 2019 | |
| Abbvie INC. | $66.74 | 2025 | |
| Alk-Abello, INC | $43.49 | 2025 | Odactra, Grastek, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $34.46 | 2025 | Elaprase |
| Greer Laboratories, INC. | $22.24 | 2025 | Oralair |
| Amgen INC. | $20.06 | 2025 | |
| Optinose US, INC. | $17.36 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.34 | 2025 | Zepbound |
| Intersect Ent, INC. | $14.78 | 2019 | |
| Cochlear Americas | $14.43 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.